The Scientist’s LabTalk

Translational research cannot be conducted in a vacuum. For a translational researcher to be successful, they need to build strong relationships with individuals, companies, and institutions that will provide useful support and expertise. In this episode, Linda Mathiasson, Strategic Customer Leader for Nucleic Acid Therapeutics at Cytiva, discusses the flourishing translational field of mRNA therapies and opportunities for research...

In this episode, Guangping Gao, professor and director of the Horae Gene Therapy Center at the University of Massachusetts Medical School, speaks about developing human gene therapies using recombinant adeno-associated viral vectors, scaling up these therapies, and the future of translational research.

Welcome to Building Bridges for Translational Research, a special edition podcast series produced by The Scientist’s Creative Ser...

Welcome to Building Bridges for Translational Research, a special edition podcast series produced by The Scientist’s Creative Services Team. This series is brought to you by Cytiva, a global provider of technologies and services that advance and accelerate therapeutic development, manufacturing, and delivery.

To take preclinical concepts to the market, translational researchers must build strong relationships and forge fruitful par...

Immunotherapies are promising as a holy grail for cancer treatment, but patient responses to these interventions are often variable in both solid tumors and blood cancers.

In this episode, Iris Kulbatski from The Scientist’s Creative Services Team spoke with Olli Dufva, a physician and doctoral researcher at the University of Helsinki’s Hematology Research Unit, about his work analyzing the genomic landscape of hematological cancer...

By understanding disease risk through the information found in a person’s genome, scientists can develop more effective therapeutics and clinicians can treat their patients more effectively.

In this episode, we talk to Kári Stefánsson, founder and CEO of deCODE Genetics, a Reykjavik-based biopharmaceutical company that collects and analyzes genealogical, medical, and genomic data at a national scale in order to identify variants th...

Heterogeneous disorders such as cardiovascular disease have multiple risk factors, causes, and manifestations. Having a holistic view of a patient’s unique biology potentially leads to earlier and better treatment options.

In this episode, we talk to Narimon Honarpour, vice president of Global Development at Amgen, about how human data is helping drug developers and clinicians unpack the complexities of cardiovascular disease to im...

Biobanks that house data from electronic health records or collect samples directly from participants are precious resources for researchers looking to understand health and disease and translate these discoveries into recommendations and treatments for patients.

In this episode, we talk to Nancy Cox, professor and director of the Vanderbilt Genetics Institute, about Vanderbilt’s DNA biobank, BioVU. Nancy and her fellow researchers...

Welcome to The Human Data Era, a special edition podcast series produced by The Scientist’s Creative Services Team.

This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines.

By ...

Through epigenetic mechanisms, some environmental toxicants, such as heavy metals, reversibly alter gene expression patterns that then drive cancer progression. In this episode, Yvonne Fondufe-Mittendorf discusses her work studying environmental toxicants and their effects on DNA methylation and chromatin structure.

Welcome to Exposed: Environmental Echoes in Health, a special edition podcast series produced by The Scientist’s Cr...

Substances that enter the body, such as food or chemicals, can make epigenetic changes in the germline that become inherited, affecting the health of future generations. In this episode, Heidi Lempradl discusses her work studying the effects of parental diet on their offspring.

Welcome to Exposed: Environmental Echoes in Health, a special edition podcast series produced by The Scientist’s Creative Services Team. This series is br...

Welcome to Exposed: Environmental Echoes in Health, a special edition podcast series produced by The Scientist’s Creative Services Team. This series is brought to you by Van Andel Institute, an independent biomedical research institute devoted to improving human health for generations to come.

While the human body’s cells all use the same set of instructions, they can end up with wildly different features and functions. Beyond the ...

The brain’s intractable nature makes neurodegenerative disorders challenging to study, but modern assays and technologies give scientists a fresh look at this complex organ. In this episode, Niki Spahich from The Scientist’s Creative Services Team spoke with Erdem Gültekin Tamgüney, a professor in the Institute of Physical Biology at Heinrich Heine University Dusseldorf, about technologies driving modern neuroscience research and h...

Cancer is one therapeutic area where patients cannot wait the conventional 10 or 12 years for a new therapy. For these patients, time is of the essence, and improved access to faster clinical trials can be the difference between receiving a new life-saving medicine and it being too late.

In this episode, we talk to David Raben, vice president of Global Development Oncology at Amgen, about the next generation of oncology trial desig...

With advances in genetics and other human data, researchers and doctors will one day be able to practice precision medicine. However, predicting how a patient will respond to a medicine is challenging in under-represented patients who are often not included in clinical trials. This is due in part to systemic issues that deter people from participating in research, especially those who have been historically excluded due to factors ...

Randomized clinical trials are the gold standard for evaluating the efficacy and safety of medicines, but they come with many drawbacks including high monetary and time costs, a lack of representation compared to the general public, and ethical limitations. Historically, these trials were the main mechanism to understand the effects of a medicine. But more recently, real world data from sources such as electronic health records, in...

Welcome to Innovating Clinical Trials, a special edition podcast series produced by The Scientist’s Creative Services Team. This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicine...

The ability to design proteins to perform desired functions will transform drug development. In particular, with AI and machine learning, scientists gain the ability to engineer antibody-based drugs, including multispecifics which engage multiple targets. By altering existing protein structures or developing proteins de novo, biologics will become more effective and specific.

In this episode, we talk to Suzanne Edavettal, the execu...

Naturally-occurring proteins have evolved over millions of years to perform specific functions based on their sequences and folded structures. As our understanding of science advanced, researchers began designing proteins from scratch to solve new challenges that modern societies face. 

In this episode, we talk to David Baker, director of the Institute for Protein Design at the University of Washington and one of the creators of th...

To build better biologic drugs, researchers need to understand exactly how amino acid building blocks interact with one another and fold into functional proteins. This knowledge provides insights into how to engage a drug target or develop an optimal therapeutic. Determining a protein’s structure is a laborious process in the wet lab, but thanks to machine learning, scientists can now use various algorithms to predict structure. 

I...